Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Identifying Deceptive Rx Advertising: FDA Rejects PhRMA's Criticisms Of Its Study

Executive Summary

US agency disagrees that study of consumer and healthcare professional ability to detect deceptive promos is unnecessary; final guidance on product name placement in labeling and advertisements mirrors 2013 draft.

Advertisement

Related Content

Rx Promotion Citations By US FDA Plummet; UCLA Webpage Elicits Final Letter Of 2017
Don't Sleep On DTC Compliance: FDA Dings Zolpimist Superiority Claim Vs Ambien
Rx Advertising: Can Consumers And Doctors Tell When Drug Promos Are Deceptive?
OMG! Kim Kardashian Social Media Post For Morning Sickness Drug Draws FDA Warning
FDA May Allow Fewer Mentions Of Generic Name In Drug Ads
FDA Enforcement Letters On Rx Drug Promotions Plummet In 2013

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122123

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel